Clinical summary of pediatric acute lymphoblastic leukemia patients complicated with asparaginase-associated pancreatitis in SCCLG-ALL-2016 protocol

Figures & data

Table 1. The doses of PEG-ASNase in SCCLG-ALL-2016 protocol.

	Total (times)	Induction (times)	Consolidation (times)	Re-induction (times)	Maintain (times)
Low risk	3	2	0	1	0
Middle risk	7	4	0	3	0
High risk	10	2	6	2	0

Table 2. The comparison of general clinical information between AAP patients and non-AAP patients.

Relevant clinical factors	Total (957)	AAP patients (35)	non-AAP patients (922)	P value
Sex				.596
Female	561	19	542
Male	396	16	380
Risk stratification				.066
Low risk	236	5	231
Middle risk	488	16	472
High risk	233	14	219
Average age (years)		7.03 ± 3.23	5.62 ± 3.44	.017
Immunophenotype				.514
B cell	873	33	840
T cell	84	2	82
Prognosis				–
CCR	897	30	867
Relapse	58	3	55
Death	49	3	46

Table 3. The distribution of occurrent time among 35 APP patients.

Occurrent time	Number of cases	Percentage (%)
The second time of induction regimen	9	25.71
The first time of induction regimen	6	18.18
The third time of induction regimen	5	15.15
The fourth time of induction regimen	4	12.12
The second time of reinduction regimen	4	12.12
The third time of consolidation regimen	2	6.06
The fourth time of consolidation regimen	2	6.06
The first time of consolidation regimen	1	3.03
The second time of consolidation regimen	1	3.03
The fifth time of consolidation regimen	1	3.03

Table 4. The comparison of possible risk factors that influence the recurrence of AAP among 17 patients who were re-exposed to ASNase.

Factors	Recurrent AAP (7)	Non recurrent AAP (10)	P value
Average age (years)	6.96 ± 3.36	7.21 ± 3.24	.776
Gender			.377
Male	5	5
Female	2	5
Risk group			.729
SR	1	3
IR	3	4
HR	3	3
Severity			.218
Yes	1	0
No	6	10
Insulin treatment			.787
Yes	1	1
No	6	9
Subsequent therapy			.323
PEG-ASNase	2	1
Erwinia	5	9

Figure 1. Four-year incidence of relapse in all 957 patients (left side) and the comparison between AAP and non-AAP patients (right side).

Table 5. The possible risk factors that influence the ALL-relapse among 33 AAP patients analyzed by Cox proportional-hazards model.

Parameter	HR	95% CI	P value
ASNase intensity
Low vs. High	0.262	0.016–4.347	.350
Risk stratification
Non HR vs. HR	0.106	0.006–1.860	.125
Insulin treatment
Yes vs. No			.579
Severity of AAP
Yes vs. No	1.685	0.173–16.367	.653
Recurrence of AAP
Yes vs. No			.335
Bridging HSCT
Yes vs. No			.799

Data availability statement

Datum of cases used to support the findings of this study are available from the corresponding author upon request.